Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies

NCT02219711 is registered in ClinicalTrials.gov with Mirati Therapeutics Inc. as lead sponsor.

NCT NCT02219711
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02219711 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies
Lead sponsor
Mirati Therapeutics Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2014
Completion date
April 27, 2022
Enrollment
193 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer